Skip to main navigation Skip to main content

CMH : Clinical and Molecular Hepatology

OPEN ACCESS
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS

Page Path

3
results for

"Hwa Young Choi"

Article category

Keywords

Publication year

"Hwa Young Choi"

Original Articles

Viral hepatitis

Core indicators related to the elimination of hepatitis B and C virus infection in South Korea: A nationwide study
Chang Hun Lee, Gwang Hyeon Choi, Hwa Young Choi, Sojung Han, Eun Sun Jang, Young Eun Chon, Young Chang, Kyung-Ah Kim, Do Young Kim, Hyung Joon Yim, Hye-Lin Kim, Sook-Hyang Jeong, In Hee Kim
Clin Mol Hepatol 2023;29(3):779-793.
Published online May 15, 2023
DOI: https://doi.org/10.3350/cmh.2023.0110
Background/Aims
To eliminate hepatitis B virus (HBV) and hepatitis C virus (HCV) according to the World Health Organization (WHO) criteria in 2021, this study investigated the national core indicators representing the current status of viral hepatitis B and C in South Korea.
Methods
We analyzed the incidence, linkage-to-care, treatment, and mortality rates of HBV and HCV infection using the integrated nationwide big data of South Korea.
Results
According to data from 2018–2020, the incidence of acute HBV infection in South Korea was 0.71 cases per 100,000 population; tthe linkage-to-care rate was only 39.4%. Among those who need hepatitis B treatment, the treatment rate was 67.3%, which was less than 80% reported in the WHO program index. The annual liver-related mortality due to HBV was 18.85 cases per 100,000 population, exceeding the WHO target of four; the most frequent cause of death was liver cancer (54.1%). The annual incidence of newly diagnosed HCV infection was 11.9 cases per 100,000 population, which was higher than the WHO impact target of five. Among HCV-infected patients, the linkage-to-care rate was 65.5% while the treatment rate was 56.8%, which were below the targets of 90% and 80%, respectively. The liver-related annual mortality rate due to HCV infection was 2.02 cases per 100,000 population.
Conclusions
Many of the current indicators identified in the Korean population did not satisfy the WHO criteria for validation of viral hepatitis elimination. Hence, a comprehensive national strategy should be urgently developed with continuous monitoring of the targets in South Korea.

Citations

Citations to this article as recorded by  Crossref logo
  • Implementation of an alert system for the care cascade of Hepatitis C infection in patients undergoing elective surgery
    Jae Seung Lee, Ho Soo Chun, Hye Won Lee, Mi Na Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim
    Journal of Infection and Public Health.2026; 19(2): 103076.     CrossRef
  • 2025 KASL clinical practice guidelines for management of hepatitis C
    Eun Sun Jang, Nae Yun Heo, Jae Yoon Jeong, Jung Gil Park, Do Seon Song, Eun Ju Cho, Chang Hun Lee, Jae Seung Lee, Jae Hyun Yoon, Seul Ki Han, Young Kul Jung
    Clinical and Molecular Hepatology.2026; 32(1): 1.     CrossRef
  • AI-Safe-C score: Assessing liver-related event risks in patients without cirrhosis after successful direct-acting antiviral treatment
    Huapeng Lin, Terry Cheuk-Fung Yip, Hye Won Lee, Xiangjun Meng, Jimmy Che-To Lai, Sang Hoon Ahn, Wenjing Pang, Grace Lai-Hung Wong, Lingfeng Zeng, Vincent Wai-Sun Wong, Victor de Lédinghen, Seung Up Kim
    Journal of Hepatology.2025; 82(3): 456.     CrossRef
  • Burden, trends, and predictions of liver cancer in China, Japan, and South Korea: analysis based on the Global Burden of Disease Study 2021
    Si Yang, Yujiao Deng, Yi Zheng, Jing Zhang, Dongdong He, Zhijun Dai, Changcun Guo
    Hepatology International.2025; 19(2): 441.     CrossRef
  • Contemporary awareness of viral hepatitis between 2012 and 2022 among Korean adults
    Donghee Kim, Won Kim, Aijaz Ahmed
    Clinical and Molecular Hepatology.2025; 31(1): e5.     CrossRef
  • Etiologic, epidemic, medical and economic aspects of hepatocellular carcinoma
    N. A. Vlasova, V. I. Apanasevich, E. V. Eliseeva, S. S. Startsev
    Сибирский научный медицинский журнал.2025; 45(1): 6.     CrossRef
  • HCV self-testing: Bridging screening gaps and ensuring cost-effectiveness for both high-risk and universal populations: Correspondence to editorial on “Self-testing strategy to eliminate hepatitis C as per World Health Organization’s goal: Analysis of dis
    Gyeongseon Shin, Beom Kyung Kim, SeungJin Bae, Hankil Lee, Sang Hoon Ahn
    Clinical and Molecular Hepatology.2025; 31(2): e163.     CrossRef
  • Universal self-testing as a cost-effective weapon to eliminate hepatitis C virus in the Republic of Korea: Editorial on “Self-testing strategy to eliminate hepatitis C as per World Health Organization’s goal: Analysis of disease burden and cost-effectiven
    Eun Sun Jang
    Clinical and Molecular Hepatology.2025; 31(2): 596.     CrossRef
  • Temporal and geospatial patterns of hepatitis C virus prevalence: a longitudinal examination using national health insurance service data in the Republic of Korea (2005–2022)
    Hwa Young Choi, Moran Ki
    BMC Public Health.2025;[Epub]     CrossRef
  • Correspondence to letter to the editor on “Contemporary awareness of viral hepatitis between 2012 and 2022 among Korean adults”
    Chang Hun Lee, In Hee Kim, Sook-Hyang Jeong
    Clinical and Molecular Hepatology.2025; 31(2): e149.     CrossRef
  • Incidence of Osteopenia or Osteoporosis in Asian Patients With Chronic Hepatitis B
    Hye Won Lee, Sungshin Kwon, Yeo Rae Moon, Hyunjung Ahn, Juyeon Lee, Sang‐Hoon Ahn
    Journal of Gastroenterology and Hepatology.2025; 40(6): 1586.     CrossRef
  • A 2024 global report on national policy, programmes, and progress towards hepatitis B elimination: findings from 33 hepatitis elimination profiles
    Lindsey Hiebert-Suwondo, Jana Manning, Rania A Tohme, Maria Buti, Loreta A Kondili, C Wendy Spearman, Nishi Prabdial-Sing, Victoria Turnier, Jeffrey V Lazarus, Imam Waked, John W Ward, Angelica Miranda, Aya Sugiyama, Behzad Hajarizadeh, Carlos Varaldo, Ca
    The Lancet Gastroenterology & Hepatology.2025; 10(7): 671.     CrossRef
  • Service delivery models and care cascade outcomes for people living with chronic hepatitis B: a global systematic review and meta-analysis
    Alexander J Stockdale, Bethany Holt, Ajeet Singh Bhadoria, Abhishek Sadasivan, Daniel Ikeda, Todd Pollack, Janus P Ong, Thuy Pham, David B Duong, Vy Nguyen, Gibril Ndow, Roger Chou, Philippa Easterbrook
    The Lancet Gastroenterology & Hepatology.2025; 10(11): 1013.     CrossRef
  • Prevalence, Clinical Characteristics, and Treatment Status of Hepatitis C Virus Infection among People Who Use Drugs in South Korea: A Prospective Multicenter Study
    Gwang Hyeon Choi, Young-Hoon Chon, Do Hoon Kwon, Sung Nam Jo, Og-Jin Jang, Kyung-Ah Kim, Dahye Baik, Eun Sun Jang, Sook-Hyang Jeong
    Gut and Liver.2025; 19(5): 725.     CrossRef
  • Etiological, Epidemiological, and Medical-Economic Aspects of Hepatocellular Carcinoma (A Review)
    N. A. Vlasova, V. I. Apanasevich, E. V. Eliseeva, S. S. Startsev
    Cell and Tissue Biology.2025; 19(6): 525.     CrossRef
  • Monitoring and evaluation of community interventions for viral hepatitis among migrants and refugees: a Delphi-based study
    Domenico Pascucci, Aina Nicolàs, Abdelrahman Taha, Jeffrey V Lazarus, Matteo Di Pumpo, Vittoria Tricomi, Francesco Di Berardino, Carlo La Vecchia, José A Perez-Molina, Giuseppe Colucci, Camila A Picchio, Angelo Maria Pezzullo, Stefania Boccia
    Journal of Global Health.2025;[Epub]     CrossRef
  • Disease burden of chronic hepatitis B and C patients in South Korea: a population-based 16-year cohort study
    Oeuk Jeong, Changhee Chu, Jungyeon Kim, Jae Seung Lee, Jun Yong Park, Kyung Eun Lee, Jaehyun Seong, Min Jin Go
    BMC Infectious Diseases.2025;[Epub]     CrossRef
  • Effect of direct-acting antivirals on disease burden of hepatitis C virus infection in South Korea in 2007–2021: a nationwide, multicentre, retrospective cohort study
    Won Sohn, Soo Young Park, Tae Hee Lee, Young Eun Chon, In Hee Kim, Byung-Seok Lee, Ki Tae Yoon, Jae Young Jang, Yu Rim Lee, Su Jong Yu, Won-Mook Choi, Sang Gyune Kim, Dae Won Jun, Joonho Jeong, Ji Hoon Kim, Eun Sun Jang, Hwi Young Kim, Sung Bum Cho, Byoun
    eClinicalMedicine.2024; 73: 102671.     CrossRef
  • Linvencovir: Paving the way for functional cure in hepatitis B
    Jiwon Yang, Jonggi Choi
    Clinical and Molecular Hepatology.2024; 30(2): 164.     CrossRef
  • Higher FIB-4 index at baseline predicts development of liver cancer in a community-based cohort with viral hepatitis
    Makiko Kimura, Tomoki Nishikawa, Tetsuro Shimakami, Takeshi Terashima, Rika Horii, Masako Fukuda, Mika Yoshita, Noboru Takata, Tomoyuki Hayashi, Masaya Funaki, Kouki Nio, Hajime Takatori, Kuniaki Arai, Tatsuya Yamashita, Masao Honda, Junko Tanaka, Shuichi
    Global Health & Medicine.2024; 6(6): 404.     CrossRef
  • Activation of Nrf2 and FXR via Natural Compounds in Liver Inflammatory Disease
    Marta Belka, Aleksandra Gostyńska-Stawna, Maciej Stawny, Violetta Krajka-Kuźniak
    International Journal of Molecular Sciences.2024; 25(20): 11213.     CrossRef
  • Correspondence to editorial on “Core indicators related to the elimination of hepatitis B and C virus infection in South Korea: A nationwide study”
    Chang Hun Lee, In Hee Kim, Sook-Hyang Jeong
    Clinical and Molecular Hepatology.2024; 30(4): 997.     CrossRef
  • Elimination of viral hepatitis: How far are we?: Editorial on “Core indicators related to the elimination of hepatitis B and C virus infection in South Korea: A nationwide study”
    Eun Ju Cho
    Clinical and Molecular Hepatology.2024; 30(4): 663.     CrossRef
  • 9,551 View
  • 223 Download
  • 21 Web of Science
  • Crossref

Viral hepatitis

A cost-effectiveness study of universal screening for hepatitis C virus infection in South Korea: A societal perspective
Hye-Lin Kim, Kyung-Ah Kim, Gwang Hyun Choi, Eun Sun Jang, Moran Ki, Hwa Young Choi, Sook-Hyang Jeong
Clin Mol Hepatol 2022;28(1):91-104.
Published online November 5, 2021
DOI: https://doi.org/10.3350/cmh.2021.0236
Background/Aims
This study aimed to evaluate the cost-effectiveness of hepatitis C virus (HCV) screening compared to no screening in the Korean population from societal and healthcare system perspectives.
Methods
A published decision-tree plus Markov model was used to compare the expected costs and quality-adjusted life years (QALY) between one-time universal HCV screening and no screening in the population aged 40–65 years using the National Health Examination (NHE) program. Input parameters were obtained from analyses of the National Health Insurance claims data, Korean HCV cohort data, or from the literature review. The population aged 40–65 years was simulated in a model spanning a lifetime from both the healthcare system and societal perspectives, which included the cost of productivity loss due to HCV-related deaths. The incremental cost-effectiveness ratio (ICER) between universal screening and no screening was estimated.
Results
The HCV screening strategy had an ICER of $2,666/QALY and $431/QALY from the healthcare system and societal perspectives, respectively. Both ICERs were far less than the willingness-to-pay threshold of $25,000/QALY, showing that universal screening was highly cost-effective compared to no screening. In various sensitivity analyses, the most influential parameters on cost-effectiveness were the antibodies to HCV (anti-HCV) prevalence, screening costs, and treatment acceptance; however, all ICERs were consistently less than the threshold. If the anti-HCV prevalence was over 0.18%, screening could be cost-effective.
Conclusions
One-time universal HCV screening in the Korean population aged 40–65 years using NHE program would be highly cost-effective from both healthcare system and societal perspectives.

Citations

Citations to this article as recorded by  Crossref logo
  • Implementation of an alert system for the care cascade of Hepatitis C infection in patients undergoing elective surgery
    Jae Seung Lee, Ho Soo Chun, Hye Won Lee, Mi Na Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim
    Journal of Infection and Public Health.2026; 19(2): 103076.     CrossRef
  • Public value judgments about the criteria for reimbursement of medicines in South Korea
    Kyung-Bok Son
    Expert Review of Pharmacoeconomics & Outcomes Research.2025; 25(1): 53.     CrossRef
  • Economic evaluation of mass screening as a strategy for hepatitis C virus elimination in South Korea
    Hwa Young Choi, Kyung-Ah Kim, Bo Young Park, Bo Youl Choi, Moran Ki
    Journal of Infection and Public Health.2025; 18(3): 102662.     CrossRef
  • Self-testing strategy to eliminate hepatitis C as per World Health Organization’s goal: Analysis of disease burden and cost-effectiveness
    Gyeongseon Shin, Beom Kyung Kim, SeungJin Bae, Hankil Lee, Sang Hoon Ahn
    Clinical and Molecular Hepatology.2025; 31(1): 166.     CrossRef
  • Universal self-testing as a cost-effective weapon to eliminate hepatitis C virus in the Republic of Korea: Editorial on “Self-testing strategy to eliminate hepatitis C as per World Health Organization’s goal: Analysis of disease burden and cost-effectiven
    Eun Sun Jang
    Clinical and Molecular Hepatology.2025; 31(2): 596.     CrossRef
  • HCV self-testing: Bridging screening gaps and ensuring cost-effectiveness for both high-risk and universal populations: Correspondence to editorial on “Self-testing strategy to eliminate hepatitis C as per World Health Organization’s goal: Analysis of dis
    Gyeongseon Shin, Beom Kyung Kim, SeungJin Bae, Hankil Lee, Sang Hoon Ahn
    Clinical and Molecular Hepatology.2025; 31(2): e163.     CrossRef
  • Cost-Effectiveness of Screening and Treating Chronic Hepatitis C Virus Infection in Zimbabwe
    Blessing Dzingirai, Leolin Katsidzira, Maarten J. Postma, Marinus van Hulst, Nyashadzaishe Mafirakureva
    International Journal of Environmental Research and Public Health.2025; 22(4): 509.     CrossRef
  • Cost-effectiveness and return on investment of hepatitis C virus elimination in China: A modelling study
    Meiyu Wu, Jing Ma, Xuehong Wang, Sini Li, Chongqing Tan, Ouyang Xie, Andong Li, Aaron G Lim, Xiaomin Wan
    Clinical and Molecular Hepatology.2025; 31(2): 394.     CrossRef
  • Cost–benefit analysis of universal screening for HCV infection in China: a Markov modelling study
    Dachuang Zhou, Liangxiu Xu, Yimei Zhong, Zhehong Xu, Jun Wang, Yuntian Wang, Yiyang Gao, Jing Xie, Yuting Xia, Wenxi Tang
    BMC Health Services Research.2025;[Epub]     CrossRef
  • HCV elimination in hyperendemic areas: Experiences in Taiwan
    Chia-Yen Dai, Chung-Feng Huang, Wan-Long Chuang, Ming-Lung Yu
    Journal of the Formosan Medical Association.2025; 124: S113.     CrossRef
  • Universal screening for HCV infection in China: An effectiveness and cost-effectiveness analysis
    Hua Zhou, Mengxia Yan, Datian Che, Bin Wu
    JHEP Reports.2024; 6(4): 101000.     CrossRef
  • Hepatitis C virus infection in patients undergoing surgery in a single tertiary academic center
    Jae Seung Lee, Hye Won Lee, Mi Na Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim
    Journal of Gastroenterology and Hepatology.2024; 39(6): 1155.     CrossRef
  • Improving the hepatitis C virus care cascade with the in‐hospital Reflex tEsting ALarm‐C (REAL‐C) model
    Jonggi Choi, Jina Park, Won‐Mook Choi, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young‐Suk Lim, Han Chu Lee, Sujin Kwon, Sang‐Hyun Hwang
    Liver International.2024; 44(5): 1243.     CrossRef
  • A cost analysis of a simplified model for HCV screening and treatment at a tertiary hospital in Zimbabwe
    Blessing Dzingirai, Leolin Katsidzira, Vongai Mwanesani, Maarten Jacobus Postma, Marinus van Hulst, Nyashadzaishe Mafirakureva
    Expert Review of Pharmacoeconomics & Outcomes Research.2024; 24(5): 687.     CrossRef
  • Contemporary Insights into Hepatitis C Virus: A Comprehensive Review
    Malik Sallam, Roaa Khalil
    Microorganisms.2024; 12(6): 1035.     CrossRef
  • Prognosis Following Sustained Virologic Response in Korean Chronic Hepatitis C Patients Treated with Sofosbuvir-Based Treatment: Data from a Multicenter Prospective Observational Study up to 7 Years
    Yewan Park, Seong-Kyun Na, Jae-Hyun Yoon, Sung-Eun Kim, Ji-Won Park, Gi-Ae Kim, Hyo-Young Lee, Young-Sun Lee, Jeong-Han Kim
    Medicina.2024; 60(7): 1132.     CrossRef
  • Correspondence to editorial on “Core indicators related to the elimination of hepatitis B and C virus infection in South Korea: A nationwide study”
    Chang Hun Lee, In Hee Kim, Sook-Hyang Jeong
    Clinical and Molecular Hepatology.2024; 30(4): 997.     CrossRef
  • Response to antiviral therapy for chronic hepatitis C and risk of hepatocellular carcinoma occurrence in Japan: a systematic review and meta-analysis of observational studies
    Yoko Yamagiwa, Keitaro Tanaka, Keitaro Matsuo, Keiko Wada, Yingsong Lin, Yumi Sugawara, Tetsuya Mizoue, Norie Sawada, Hidemi Takimoto, Hidemi Ito, Tetsuhisa Kitamura, Ritsu Sakata, Takashi Kimura, Shiori Tanaka, Manami Inoue, Sarah Krull Abe, Shuhei Nomur
    Scientific Reports.2023;[Epub]     CrossRef
  • Global burden of primary liver cancer and its association with underlying aetiologies, sociodemographic status, and sex differences from 1990–2019: A DALY-based analysis of the Global Burden of Disease 2019 study
    Sungchul Choi, Beom Kyung Kim, Dong Keon Yon, Seung Won Lee, Han Gyeol Lee, Ho Hyeok Chang, Seoyeon Park, Ai Koyanagi, Louis Jacob, Elena Dragioti, Joaquim Radua, Jae Il Shin, Seung Up Kim, Lee Smith
    Clinical and Molecular Hepatology.2023; 29(2): 433.     CrossRef
  • Comorbidities and the use of comedications among patients with chronic hepatitis C in Korea: A nationwide cross-sectional study
    Kyung Min Kwon, Jae-Jun Shim, Gi-Ae Kim, Bo Ok Kim, Helin Han, Hyun Jung Ahn
    The Korean Journal of Internal Medicine.2023; 38(3): 338.     CrossRef
  • Core indicators related to the elimination of hepatitis B and C virus infection in South Korea: A nationwide study
    Chang Hun Lee, Gwang Hyeon Choi, Hwa Young Choi, Sojung Han, Eun Sun Jang, Young Eun Chon, Young Chang, Kyung-Ah Kim, Do Young Kim, Hyung Joon Yim, Hye-Lin Kim, Sook-Hyang Jeong, In Hee Kim
    Clinical and Molecular Hepatology.2023; 29(3): 779.     CrossRef
  • Real-life experience of ledipasvir and sofosbuvir for HCV infected Korean patients: a multicenter cohort study
    Soon Kyu Lee, Sung Won Lee, Hae Lim Lee, Hee Yeon Kim, Chang Wook Kim, Do Seon Song, U Im Chang, Jin Mo Yang, Sun Hong Yoo, Jung Hyun Kwon, Soon Woo Nam, Seok-Hwan Kim, Myeong Jun Song, Jaejun Lee, Hyun Yang, Si Hyun Bae, Ji Won Han, Heechul Nam, Pil Soo
    The Korean Journal of Internal Medicine.2022; 37(6): 1167.     CrossRef
  • Finding Cases of Hepatitis C for Treatment Using Automated Screening in the Emergency Department is Effective, but What Is the Cost?
    David Stephen Prince, Julia Di Girolamo, Joseph Louis Pipicella, Melissa Bagatella, Tahrima Kayes, Frank Alvaro, Michael Maley, Hong Foo, Paul MacConachie Middleton, Miriam Tania Levy, Yu-Chen Fan
    Canadian Journal of Gastroenterology and Hepatology.2022; 2022: 1.     CrossRef
  • How to Optimize the Care Cascade of Hepatitis C Virus Infection
    Beom Kyung Kim
    Gut and Liver.2022; 16(6): 809.     CrossRef
  • 15,453 View
  • 236 Download
  • 25 Web of Science
  • Crossref

Viral hepatitis

Comparison and analysis of the prevalence of hepatitis C virus infection by region in the Republic of Korea during 2005-2012
Hae-Sook Shon, Hwa Young Choi, Jang Rak Kim, So Yeon Ryu, Youn-Jae Lee, Myeong Jin Lee, Hyun Ju Min, Jun Lee, Yeong Jun Song, Moran Ki
Clin Mol Hepatol 2015;21(3):249-256.
Published online September 30, 2015
DOI: https://doi.org/10.3350/cmh.2015.21.3.249
Background/Aims

This study compared the prevalence of hepatitis C virus (HCV) infection in the Republic of Korea and estimated the high-risk regions and towns.

Methods

National Health Insurance Service data for 8 years from 2005 to 2012 were used. The subjects of the study had visited medical facilities and been diagnosed with or received treatment for acute or chronic HCV as a primary or secondary disease according to ICD-10 codes of B17.1 or B18.2, respectively. Any patient who received treatment for the same disease multiple times during 1 year was counted as one patient in that year. To correct for the effect of the age structure of the population by year and region, the age-adjusted prevalence was calculated using the direct method based on the registered population in 2010.

Results

The overall prevalence of HCV infection among Korean adults (>20 years old) increased from 0.14% in 2005 to 0.18% in 2012. The sex-, age-, and region-adjusted prevalence in 2012 was 0.18%. The prevalence was highest in Busan, Jeonnam, and Gyeongnam, and there were towns with noticeably higher prevalences within these regions: Jindo (0.97%) in Jeonnam, Namhae (0.90%) in Gyeongnam, and Seo-gu (0.86%) in Busan.

Conclusions

The prevalence of HCV infection differs by regions as well as towns in the Republic of Korea, and is highest in Busan, Jeonnam, and Gyeongnam. The reasons for the high prevalence in these specific regions should be identified, since this could help prevent HCV infections in the future. In addition, active surveillance and treatment policies should be introduced to stop any further spread of infection in these high-prevalence regions.

Citations

Citations to this article as recorded by  Crossref logo
  • Economic evaluation of mass screening as a strategy for hepatitis C virus elimination in South Korea
    Hwa Young Choi, Kyung-Ah Kim, Bo Young Park, Bo Youl Choi, Moran Ki
    Journal of Infection and Public Health.2025; 18(3): 102662.     CrossRef
  • Insights into the spatial epidemiology of hepatitis C infection: systematic synthesis of area-level determinants and spatiotemporal analyses
    Jacob Mugoya Gizamba, Brian Karl Finch, Siqin Wang, Jeffrey D. Klausner
    BMC Public Health.2025;[Epub]     CrossRef
  • Temporal and geospatial patterns of hepatitis C virus prevalence: a longitudinal examination using national health insurance service data in the Republic of Korea (2005–2022)
    Hwa Young Choi, Moran Ki
    BMC Public Health.2025;[Epub]     CrossRef
  • Comorbidities and the use of comedications among patients with chronic hepatitis C in Korea: A nationwide cross-sectional study
    Kyung Min Kwon, Jae-Jun Shim, Gi-Ae Kim, Bo Ok Kim, Helin Han, Hyun Jung Ahn
    The Korean Journal of Internal Medicine.2023; 38(3): 338.     CrossRef
  • Clinical and histopathological analyses of kidney biopsies in a single center for 7 years
    Seunghye Lee, Sehyun Jung, Mi-Ji Kim, Jong Sil Lee, Ha Nee Jang, Se-Ho Chang, Hyun-Jung Kim
    Medicine.2022; 101(29): e29695.     CrossRef
  • The predictors of sustained virological response with sofosbuvir and ribavirin in patients with chronic hepatitis C genotype 2
    Sung Yong Han, Hyun Young Woo, Jeong Heo, Sang Gyu Park, Sung Ik Pyeon, Young Joo Park, Dong Uk Kim, Gwang Ha Kim, Hyung Hoi Kim, Geun Am Song, Mong Cho
    The Korean Journal of Internal Medicine.2021; 36(3): 544.     CrossRef
  • The changing epidemiology of liver diseases in the Asia–Pacific region
    Martin C. S. Wong, Jason L. W. Huang, Jacob George, Junjie Huang, Colette Leung, Mohammed Eslam, Henry L. Y. Chan, Siew C. Ng
    Nature Reviews Gastroenterology & Hepatology.2019; 16(1): 57.     CrossRef
  • Apolipoprotein E Genotype and Expression Correlated with Hepatitis C Virus Genotype and Infection
    Gyu-Nam Park, Hyun-Jung Jo, Hye-Ran Kim, Min-Ju Kim, Kyung-A Shin, Seung-Bok Hong, Kyung-Soo Chang
    Journal of Bacteriology and Virology.2019; 49(1): 27.     CrossRef
  • Incidence and Overall Survival of Biliary Tract Cancers in South Korea from 2006 to 2015: Using the National Health Information Database
    Byung-Woo Kim, Chang-Mo Oh, Hwa Young Choi, Joong-Won Park, Hyunsoon Cho, Moran Ki
    Gut and Liver.2019; 13(1): 104.     CrossRef
  • Why is Life Expectancy in Busan Shorter than in Seoul? Age and Cause-Specific Contributions to the Difference in Life Expectancy between Two Cities
    Young-Ho Khang, Jinwook Bahk
    Yonsei Medical Journal.2019; 60(7): 687.     CrossRef
  • Incidence and Prognosis of Subsequent Cholangiocarcinoma in Patients with Hepatic Resection for Bile Duct Stones
    Hyun Jung Kim, Tae Uk Kang, Heather Swan, Min Ji Kang, Nayoung Kim, Hyeong Sik Ahn, Seon Mee Park
    Digestive Diseases and Sciences.2018; 63(12): 3465.     CrossRef
  • Understanding the complications of anti‐tumor necrosis factor therapy in East Asian patients with inflammatory bowel disease
    Jae Hee Cheon
    Journal of Gastroenterology and Hepatology.2017; 32(4): 769.     CrossRef
  • Current status of hepatitis C virus infection and countermeasures in South Korea
    Sook-Hyang Jeong, Eun Sun Jang, Hwa Young Choi, Kyung-Ah Kim, Wankyo Chung, Moran Ki
    Epidemiology and Health.2017; 39: e2017017.     CrossRef
  • Efficacy and safety of sofosbuvir-based regimens for treatment in chronic hepatitis C genotype 1 patients with moderately impaired renal function
    Hyun Phil Shin, Ji-Ae Park, Blaire Burman, Richard A. Kozarek, Asma Siddique
    Clinical and Molecular Hepatology.2017; 23(4): 316.     CrossRef
  • Increased survival in hepatitis c patients who underwent living donor liver transplant: a case-control study with propensity score matching
    Jong Man Kim, Kwang-Woong Lee, Gi-Won Song, Bo-Hyun Jung, Hae Won Lee, Nam-Joon Yi, Choon Hyuck David Kwon, Shin Hwang, Kyung-Suk Suh, Jae-Won Joh, Suk-Koo Lee, Sung-Gyu Lee
    Annals of Surgical Treatment and Research.2017; 93(6): 293.     CrossRef
  • 12,134 View
  • 89 Download
  • 16 Web of Science
  • Crossref